Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis. J of Skin [Internet]. 2023 Mar. 13 [cited 2025 Apr. 18];7(2):s154. Available from: https://skin.dermsquared.com/skin/article/view/1980